Financial Data and Key Metrics Changes - In Q4 2025, the company reported sales of $751 million, with core sales increasing by 10.8% year-over-year, benefiting from foreign exchange (FX) which added nearly 400 basis points [15][19] - Adjusted EBITDA margin for Q4 was 14.8%, a 90 basis point improvement from the previous year, driven by volume, price, and productivity [16][21] - Adjusted EPS for Q4 was $0.38, up more than 50% from Q4 2024, supported by strong operating profits and share repurchases [13][16] - For the full year 2025, sales reached $2.7 billion, with core sales increasing by 6.5% [17][18] - Adjusted EBITDA for 2025 was up 26%, resulting in a margin of around 14%, a 2-point improvement over 2024 [13][18] Business Line Data and Key Metrics Changes - Specialty products and technologies revenue grew nearly 16% year-over-year, with core sales up 10.9% [22] - The orthodontics business, including Spark, saw high single-digit growth, with brackets and wires up double digits year-over-year [22][24] - The implants segment grew mid-single digits globally, with strong performance in digital and regenerative segments [22] - Equipment and consumables segment core sales increased by 10.7%, with diagnostics core sales up double digits globally [24] Market Data and Key Metrics Changes - The North American diagnostic market returned to growth in the second half of 2025, marking the third consecutive quarter of positive growth across all business lines [31][32] - The overall implant market is estimated to be growing mid-single digits, with the company slightly outperforming this in Q4 [70] Company Strategy and Development Direction - The company is focused on a value creation plan aimed at achieving 2%-4% core growth, 4%-7% EBITDA growth, and 7%-10% EPS growth, with a free cash flow conversion target of 100% or better [7][14] - Continued investment in R&D and new product launches is a priority, with a strong pipeline for 2026 [12][31] - The company aims to maintain its competitive edge by enhancing customer training and product offerings [71] Management's Comments on Operating Environment and Future Outlook - Management noted that the dental market remains slow but stable, with signs of improvement beginning to emerge [31][32] - The company expects core revenue growth of 2%-4% for 2026, aligning with medium-term financial objectives [14][26] - Risks include macroeconomic volatility and uncertainties in the Chinese market, particularly regarding value-based pricing (VBP) [41][54] Other Important Information - The company implemented a $250 million share repurchase program in early 2025, returning over $160 million to shareholders throughout the year [9][25] - Free cash flow for 2025 was $231 million, with a conversion rate of 114% [25] Q&A Session Summary Question: Guidance and potential upsides/risks - Management discussed the guidance for 2026, highlighting potential upsides from market momentum and pricing, while noting risks from macro volatility and the Chinese market [35][41] Question: Tax rate expectations - The expected non-GAAP tax rate for 2026 is around 28%, with potential for further reductions depending on U.S. profitability and debt management [47][49] Question: VBP assumptions for ortho and implants - Management expects first-round VBP for ortho and second-round for implants in 2026, but specific timing remains uncertain [52][54] Question: Spark growth and profitability - Spark continues to outgrow the market, with profitability consistent with previous quarters, driven by new product introductions and customer training [78]

Summary of Envista's Conference Call Industry Overview - The dental market is characterized as "soft but stable," with low single-digit growth observed over the past four quarters [2][3] - The consumables market has shown the most consistency, with low single-digit growth [3] - Orthodontics is experiencing low to mid-single-digit growth, with brackets and wires performing well [3] - The implant market is growing steadily, with a focus on digitization and equipment sales [4] - Diagnostics have been a negative low single-digit market but are showing signs of improvement [4] Company Performance - Envista has achieved approximately 5% growth year-to-date, with trends continuing positively into the fourth quarter [6][7] - December is a significant month for purchasing, and a strong finish to the year is anticipated [7] - The Spark business is expected to grow, with a consistent global aligner market performance [9][10] Product Innovations and Strategies - Envista has focused on providing a full solution to orthodontists, combining aligners with brackets and wires [10][11] - New product introductions, such as Spark On Demand and BiteSync, are aimed at enhancing treatment options and efficiency [12][13] - Continuous innovation is a key strategy, with a focus on both line extensions and new product launches [15] Financial Insights - The Spark business had a $45 million revenue headwind last year, with a significant portion expected to return this year [18][19] - A 20% year-over-year cost reduction in aligner production has been achieved through automation [21][22] - Envista's G&A expenses have decreased by 12% year-to-date, with expectations to maintain flat spending going forward [55] Market Dynamics - North America is recovering positively, while Europe continues to perform well [4][5] - China remains uncertain, with ongoing questions about market dynamics [5] - The diagnostics market is expected to recover modestly, driven by interest rate reductions and consumer confidence [47] R&D and Acquisitions - Envista invested $25 million in R&D for implants, focusing on commercial and clinical improvements [28] - Two acquisitions were made to enhance geographic penetration and product offerings in the implant space [33] Capital Deployment and Future Outlook - Envista aims for organic growth as the primary capital deployment strategy, with M&A opportunities also being a priority [62] - A share repurchase program of $250 million over two years has been approved [63] - The company anticipates a lower tax rate in 2026 due to improved profitability and the resolution of intercompany loans [58][59] Conclusion - Envista is positioned for continued growth through innovation, strategic acquisitions, and a focus on operational efficiency, with a positive outlook for 2026 and beyond [64][65]

Summary of Henry Schein Conference Call Company Overview - **Company**: Henry Schein - **Industry**: Dental and Medical Distribution Key Points Industry Trends - Stronger growth observed in international dental markets compared to the U.S. in Q3, with notable performance in Canada, Brazil, and Southern Europe [3][4] - The trend of international markets outperforming the U.S. is expected to continue into Q4, with stable growth anticipated [3][4] - Digital equipment is a primary growth driver in the U.S. dental market, with Q4 typically being a strong seasonal quarter [4] Specialty Products and Market Share - Specialty products in the U.S. are showing improvement, with market share gains noted in a stable market [8][9] - The value segment of implants is growing faster than the premium segment, driven by cost-conscious general practitioners (GPs) and dental service organizations (DSOs) [20] - The Taper Per Conical implant accounts for one-third of U.S. implant revenue, with potential to grow to 50% over time [21] Cost Savings Initiatives - Henry Schein is targeting $200 million in net cost improvements over the next few years, with some upfront costs expected [10][11] - The savings will be phased in thoughtfully to ensure optimal execution, with benefits anticipated to grow beyond 2026 [12][13] - The focus is on both cost of goods sold (COGS) and operating expenses (OPEX), with initiatives aimed at dynamic pricing and private label growth [16][17] E-commerce Platform - A new global e-commerce platform is being rolled out, starting in the U.K. and Ireland, aimed at enhancing customer experience and capturing new sales [29][30] - Initial results from the U.K. launch are encouraging, with positive customer satisfaction and engagement metrics [30][31] - The platform is expected to improve order efficiency and profitability, with a high percentage of orders already being processed electronically [33][34] Financial Performance and Guidance - Q3 revenue showed a sequential increase of $100 million compared to Q2, with expectations for continued growth into Q4 [37] - The company anticipates mid-single-digit revenue growth for 2026, influenced by ongoing market momentum and internal initiatives [46][47] - EBIT growth is expected to return in Q4 2025 compared to Q4 2024, driven by restructuring benefits and improved operating margins [48] Medical Segment - The medical segment is stabilizing with a reported growth of 4.7% in Q3, aligning with mid-single-digit growth expectations [51] - The shift towards alternative care settings is benefiting Henry Schein, particularly in the home solutions segment [52] Capital Allocation and M&A Strategy - Henry Schein remains open to acquisitions that align with its strategy, focusing on opportunities that enhance integration and revenue growth [54] Additional Insights - The company is investing in technology and cloud-based solutions to enhance practice management systems, contributing to high single-digit growth in this segment [39][40] - The orthodontics business is not seen as a major growth driver, with a focus shifting towards implants and endodontics [28] This summary encapsulates the key insights and data points from the Henry Schein conference call, highlighting the company's performance, strategic initiatives, and market trends.

Financial Performance - Net sales were $936 million, a decrease of 4.9% year-over-year[12] - Constant currency net sales decreased by 6.7% year-over-year, including a 3.2% impact from Byte[10, 14] - Adjusted EBITDA was $197 million, a 14.6% increase year-over-year, with a margin of 21.1%, up 360 bps year-over-year[12, 14] - Adjusted EPS was $0.52, a 6.6% increase year-over-year[10, 14] - Operating cash flow was $48 million, a 77% decrease year-over-year[12] Segment Performance - Essential Dental Solutions (EDS) sales were $387 million, a reported increase of 2.9% and a constant currency increase of 1.1%[17] - Orthodontic and Implant Solutions (OIS) sales were $226 million, a reported decrease of 18.1% and a constant currency decrease of 19.4%, including a ~$35 million Byte impact[17] - Connected Technology Solutions (CTS) sales were $243 million, a reported decrease of 3.8% and a constant currency decrease of 5.9%[17] - Wellspect Healthcare sales were $80 million, a reported increase of 1.2% and a constant currency decrease of 2.5%, including a ~4.5% impact from prior year U S distributor initial stocking order[17] Regional Performance - U S net sales were $293 million, a constant currency decrease of 18.3%, including a 7.7% Byte impact[10] - Europe net sales were $404 million, a constant currency decrease of 0.4%[10] - Rest of World net sales were $239 million, a constant currency increase of 0.5%[10] Outlook - The company reaffirmed its FY2025 outlook, with constant currency growth between (4.0%) and (2.0%), including a (2.0%) Byte impact[19] - The company reaffirmed its FY2025 outlook, with reported sales between $3.60 billion and $3.70 billion[19] - The company reaffirmed its FY2025 outlook, with adjusted EBITDA margin greater than 19% and adjusted EPS between $1.80 and $2.00[19]